ECTRIMS eLearning

Studies of circumpapillary retinal nerve fiber layer and macular ganglion cell-inner plexiform layer thickness losses in multiple sclerosis, neuromyelitis optica, and anti-myelin oligodendrocyte glycoprotein positive patients
Author(s): ,
N Mekhasingharak
Affiliations:
Ophthalmology, Naresuan University, Phitsanulok
,
P Laowanapiban
Affiliations:
Ophthalmology, Mettapracharak Hospital, Nakhon Pathom
,
N Prayoonwiwat
Affiliations:
Neurology, Siriraj Hospital, Mahidol University
,
S Siritho
Affiliations:
Neurology, Bumrungrad International Hospital, Bangkok & Siriraj Hospital, Mahidol University
,
C Satukijchai
Affiliations:
Neurology, Siriraj Hospital, Mahidol University
N Chirapapaisan
Affiliations:
Ophthalmology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
ECTRIMS Learn. Mekhasingharak N. 09/16/16; 146057; P1629
Nattapong Mekhasingharak
Nattapong Mekhasingharak
Contributions
Abstract

Abstract: P1629

Type: LB Poster

Abstract Category: Late Breaking News

Background: Optic neuritis (ON) can result from many underlying conditions. Multiple sclerosis (MS) and neuromyelitis optica (NMO) are well-known causes of ON. There are, however, many unknown or not clearly understood underlying conditions, such as myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) related ON. Optical coherence tomography (OCT) can detect retinal nerve fiber layer (RNFL) and ganglion cell layer thinning after ON.

Objective: To investigate the thickness of peripapillary RNFL and macular ganglion cell-inner plexiform layers (GCIPL) using OCT in MS, NMO spectrum disorder with AQP4 antibody, and anti-MOG positive patients

Methods: Eighty-one previous ON eyes (43 NMO-ON, 10 MS-ON, 7 anti-MOG positive ON, and 21 idiopathic-ON) and 28 non-ON eyes (13 NMO, 8 MS, 1 anti-MOG positive, and 6 idiopathic-non-ON) were included in this study. All patients underwent SD-OCT imaging to analyze RNFL and GCIPL thickness after at least 3 months since the last episode of acute ON.

Results: Average RNFL and GCIPL thicknesses were thinner in NMO-ON, anti-MOG positive ON, and idiopathic-ON eyes when compared with those of MS-ON eyes ( p=0.006, p< 0.001, and p=0.041 respectively). All quadrants of RNFL and GCIPL thicknesses (except temporal thickness) of non-MS-ON eyes were significantly thinner than those of MS-ON eyes, especially superior quadrant of RNFL. There was no statistically significant difference for RNFL or GCIPL between the NMO-ON and anti-MOG positive ON groups. After the first episode of ON, mean average RNFL thickness decreased 33.71 µm, 53.2 µm, 13.86 µm, and 25.81 µm, and mean average GCIPL thickness decreased 26.489 µm, 32.4 µm, 11.536 µm, and 24.767 µm in NMO-ON, anti-MOG positive ON, MS-ON, and idiopathic-ON, respectively. After subsequent ON attacks, visual acuity, mean deviation of visual field, and RNFL thickness in the NMO-ON group showed a trend toward worsening, but the difference was not statistically significant.

Conclusions: OCT imaging for measurement of RNFL and GCIPL thickness is better than residual visual acuity and mean deviation of visual field for differentiating MS-ON from other types of ON. Superior thinning on RNFL analysis indicates non-MS previous ON. OCT may facilitate a decision regarding whether or not the patient should be treated long-term with disease-modifying therapies for MS or immunosuppressive agents for other types of optic neuritis.

Disclosure:

Nattapong Mekhasingharak: nothing to disclose

Poramaet Laowanapiban: nothing to disclose

Naraporn Prayoonwiwat: nothing to disclose

Sasitorn Siritho: nothing to disclose

Chanjira Satukijchai: nothing to disclose

Niphon Chirapapaisan: nothing to disclose

Abstract: P1629

Type: LB Poster

Abstract Category: Late Breaking News

Background: Optic neuritis (ON) can result from many underlying conditions. Multiple sclerosis (MS) and neuromyelitis optica (NMO) are well-known causes of ON. There are, however, many unknown or not clearly understood underlying conditions, such as myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) related ON. Optical coherence tomography (OCT) can detect retinal nerve fiber layer (RNFL) and ganglion cell layer thinning after ON.

Objective: To investigate the thickness of peripapillary RNFL and macular ganglion cell-inner plexiform layers (GCIPL) using OCT in MS, NMO spectrum disorder with AQP4 antibody, and anti-MOG positive patients

Methods: Eighty-one previous ON eyes (43 NMO-ON, 10 MS-ON, 7 anti-MOG positive ON, and 21 idiopathic-ON) and 28 non-ON eyes (13 NMO, 8 MS, 1 anti-MOG positive, and 6 idiopathic-non-ON) were included in this study. All patients underwent SD-OCT imaging to analyze RNFL and GCIPL thickness after at least 3 months since the last episode of acute ON.

Results: Average RNFL and GCIPL thicknesses were thinner in NMO-ON, anti-MOG positive ON, and idiopathic-ON eyes when compared with those of MS-ON eyes ( p=0.006, p< 0.001, and p=0.041 respectively). All quadrants of RNFL and GCIPL thicknesses (except temporal thickness) of non-MS-ON eyes were significantly thinner than those of MS-ON eyes, especially superior quadrant of RNFL. There was no statistically significant difference for RNFL or GCIPL between the NMO-ON and anti-MOG positive ON groups. After the first episode of ON, mean average RNFL thickness decreased 33.71 µm, 53.2 µm, 13.86 µm, and 25.81 µm, and mean average GCIPL thickness decreased 26.489 µm, 32.4 µm, 11.536 µm, and 24.767 µm in NMO-ON, anti-MOG positive ON, MS-ON, and idiopathic-ON, respectively. After subsequent ON attacks, visual acuity, mean deviation of visual field, and RNFL thickness in the NMO-ON group showed a trend toward worsening, but the difference was not statistically significant.

Conclusions: OCT imaging for measurement of RNFL and GCIPL thickness is better than residual visual acuity and mean deviation of visual field for differentiating MS-ON from other types of ON. Superior thinning on RNFL analysis indicates non-MS previous ON. OCT may facilitate a decision regarding whether or not the patient should be treated long-term with disease-modifying therapies for MS or immunosuppressive agents for other types of optic neuritis.

Disclosure:

Nattapong Mekhasingharak: nothing to disclose

Poramaet Laowanapiban: nothing to disclose

Naraporn Prayoonwiwat: nothing to disclose

Sasitorn Siritho: nothing to disclose

Chanjira Satukijchai: nothing to disclose

Niphon Chirapapaisan: nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies